spacer
home > ebr > winter 2001 > calorimetry takes the heat off drug discovery
PUBLICATIONS
European Biopharmaceutical Review

Calorimetry Takes the Heat Off Drug Discovery

There are two essential steps at the beginning of the process of bringing a drug compound to market; the identification of a lead compound, and the optimisation of this lead compound to hone the required characteristics - including its affinity - for its specific target. The modern pharmaceutical industry is involved in a continuous search for ways of streamlining these two steps to increase yields, save time and reduce costs. As a result, there has been a pressure to develop the capabilities of instrumentation to assist in these processes. The recent revolution in the development of calorimetric instrumentation (and its applications) has enabled it to assume a position in the frontline of the battle to develop pharmaceutical products.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr John Ladbury, Wellcome Trust Senior Research Fellow in the Department
of Biochemistry and Molecular Biology at University College London

A graduate in Chemistry and Physics from the University of London, John Ladbury went on to receive his PhD in Inorganic Polymer Chemistry from the University of Greenwich in 1990. John held postdoctoral appointments at Yale University, Harvard University Medical School and New York University Medical Center before taking up a Wellcome Trust Career Development Research Fellowship at the University of Oxford in 1994. He received a Wellcome Trust Senior Fellowship after moving to the Department of Biochemistry and Molecular Biology at University College London. John's laboratory at UCL adopts a multi-disciplinary approach to understanding thermodynamic/structural correlation in the interactions of proteins. His group is currently involved in drug development projects on inhibitors of intracellular signaling pathways and novel antibacterial targets.

spacer
Dr John Ladbury
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Paradigm Clinical Research Names Industry Veteran Kurt Mussina as CEO as Expansion Plans Are Set in Motion


More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement